Brookline Capital Markets launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and price target of $25. The stock closed at $11.80 on July 24. Arcturus is developing RNA-based therapies...
Tag - ornithine transcarbamylase deficiency
